Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc. (SNDX) Stock Competitors & Peer Comparison
See (SNDX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SNDX | $23.88 | +2.23% | 2.1B | -7.26 | -$3.29 | N/A |
| VRTX | $447.26 | +0.16% | 113.6B | 29.19 | $15.32 | N/A |
| REGN | $777.25 | +0.60% | 80.8B | 18.73 | $41.49 | +0.46% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $743.12 | +1.76% | 46B | 37.93 | $19.59 | N/A |
| ALNY | $328.73 | -0.65% | 43.6B | 141.74 | $2.32 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| INSM | $164.86 | +0.82% | 35.5B | -27.34 | -$6.03 | N/A |
| UTHR | $570.27 | -3.83% | 25B | 20.47 | $27.86 | N/A |
| BNTX | $89.42 | +0.61% | 22.5B | -16.50 | -$5.42 | N/A |
Stock Comparison
SNDX vs VRTX Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, VRTX has a market cap of 113.6B. Regarding current trading prices, SNDX is priced at $23.88, while VRTX trades at $447.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas VRTX's P/E ratio is 29.19. In terms of profitability, SNDX's ROE is -2.07%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, SNDX is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check VRTX's competition here
SNDX vs REGN Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, REGN has a market cap of 80.8B. Regarding current trading prices, SNDX is priced at $23.88, while REGN trades at $777.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas REGN's P/E ratio is 18.73. In terms of profitability, SNDX's ROE is -2.07%, compared to REGN's ROE of +0.15%. Regarding short-term risk, SNDX is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check REGN's competition here
SNDX vs VRNA Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, SNDX is priced at $23.88, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas VRNA's P/E ratio is -102.80. In terms of profitability, SNDX's ROE is -2.07%, compared to VRNA's ROE of -0.30%. Regarding short-term risk, SNDX is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check VRNA's competition here
SNDX vs ARGX Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, ARGX has a market cap of 46B. Regarding current trading prices, SNDX is priced at $23.88, while ARGX trades at $743.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas ARGX's P/E ratio is 37.93. In terms of profitability, SNDX's ROE is -2.07%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, SNDX is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check ARGX's competition here
SNDX vs ALNY Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, ALNY has a market cap of 43.6B. Regarding current trading prices, SNDX is priced at $23.88, while ALNY trades at $328.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas ALNY's P/E ratio is 141.74. In terms of profitability, SNDX's ROE is -2.07%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, SNDX is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check ALNY's competition here
SNDX vs SGEN Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, SNDX is priced at $23.88, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas SGEN's P/E ratio is -57.19. In terms of profitability, SNDX's ROE is -2.07%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, SNDX is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check SGEN's competition here
SNDX vs INSM Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, INSM has a market cap of 35.5B. Regarding current trading prices, SNDX is priced at $23.88, while INSM trades at $164.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas INSM's P/E ratio is -27.34. In terms of profitability, SNDX's ROE is -2.07%, compared to INSM's ROE of -1.68%. Regarding short-term risk, SNDX is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check INSM's competition here
SNDX vs UTHR Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, UTHR has a market cap of 25B. Regarding current trading prices, SNDX is priced at $23.88, while UTHR trades at $570.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas UTHR's P/E ratio is 20.47. In terms of profitability, SNDX's ROE is -2.07%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, SNDX is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check UTHR's competition here
SNDX vs BNTX Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, BNTX has a market cap of 22.5B. Regarding current trading prices, SNDX is priced at $23.88, while BNTX trades at $89.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas BNTX's P/E ratio is -16.50. In terms of profitability, SNDX's ROE is -2.07%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, SNDX is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check BNTX's competition here
SNDX vs RPRX Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, RPRX has a market cap of 20.8B. Regarding current trading prices, SNDX is priced at $23.88, while RPRX trades at $48.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas RPRX's P/E ratio is 27.24. In terms of profitability, SNDX's ROE is -2.07%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, SNDX is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check RPRX's competition here
SNDX vs BGNE Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, SNDX is priced at $23.88, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas BGNE's P/E ratio is -22.55. In terms of profitability, SNDX's ROE is -2.07%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, SNDX is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check BGNE's competition here
SNDX vs ROIV Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, ROIV has a market cap of 19.9B. Regarding current trading prices, SNDX is priced at $23.88, while ROIV trades at $27.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas ROIV's P/E ratio is -23.79. In terms of profitability, SNDX's ROE is -2.07%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, SNDX is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check ROIV's competition here
SNDX vs MRNA Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, MRNA has a market cap of 19.8B. Regarding current trading prices, SNDX is priced at $23.88, while MRNA trades at $50.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas MRNA's P/E ratio is -6.89. In terms of profitability, SNDX's ROE is -2.07%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, SNDX is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for SNDX.Check MRNA's competition here
SNDX vs RVMD Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, RVMD has a market cap of 19.5B. Regarding current trading prices, SNDX is priced at $23.88, while RVMD trades at $98.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas RVMD's P/E ratio is -16.58. In terms of profitability, SNDX's ROE is -2.07%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, SNDX is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check RVMD's competition here
SNDX vs INCY Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, INCY has a market cap of 18.8B. Regarding current trading prices, SNDX is priced at $23.88, while INCY trades at $94.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas INCY's P/E ratio is 14.71. In terms of profitability, SNDX's ROE is -2.07%, compared to INCY's ROE of +0.29%. Regarding short-term risk, SNDX is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check INCY's competition here
SNDX vs DNA-WT Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, SNDX is priced at $23.88, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, SNDX's ROE is -2.07%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, SNDX is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check DNA-WT's competition here
SNDX vs GMAB Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, GMAB has a market cap of 16.8B. Regarding current trading prices, SNDX is priced at $23.88, while GMAB trades at $27.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas GMAB's P/E ratio is 17.68. In terms of profitability, SNDX's ROE is -2.07%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, SNDX is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check GMAB's competition here
SNDX vs BBIO Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, BBIO has a market cap of 14.4B. Regarding current trading prices, SNDX is priced at $23.88, while BBIO trades at $74.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas BBIO's P/E ratio is -19.70. In terms of profitability, SNDX's ROE is -2.07%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, SNDX is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check BBIO's competition here
SNDX vs SMMT Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, SMMT has a market cap of 14.1B. Regarding current trading prices, SNDX is priced at $23.88, while SMMT trades at $18.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas SMMT's P/E ratio is -13.14. In terms of profitability, SNDX's ROE is -2.07%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, SNDX is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check SMMT's competition here
SNDX vs ASND Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, ASND has a market cap of 14B. Regarding current trading prices, SNDX is priced at $23.88, while ASND trades at $228.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas ASND's P/E ratio is -52.59. In terms of profitability, SNDX's ROE is -2.07%, compared to ASND's ROE of +1.28%. Regarding short-term risk, SNDX is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check ASND's competition here
SNDX vs KRTX Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, SNDX is priced at $23.88, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas KRTX's P/E ratio is -28.09. In terms of profitability, SNDX's ROE is -2.07%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, SNDX is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check KRTX's competition here
SNDX vs IONS Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, IONS has a market cap of 12.4B. Regarding current trading prices, SNDX is priced at $23.88, while IONS trades at $75.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas IONS's P/E ratio is -31.57. In terms of profitability, SNDX's ROE is -2.07%, compared to IONS's ROE of -0.69%. Regarding short-term risk, SNDX is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check IONS's competition here
SNDX vs MDGL Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, MDGL has a market cap of 12.2B. Regarding current trading prices, SNDX is priced at $23.88, while MDGL trades at $529.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas MDGL's P/E ratio is -41.26. In terms of profitability, SNDX's ROE is -2.07%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, SNDX is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check MDGL's competition here
SNDX vs EXEL Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, EXEL has a market cap of 11.8B. Regarding current trading prices, SNDX is priced at $23.88, while EXEL trades at $44.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas EXEL's P/E ratio is 15.84. In terms of profitability, SNDX's ROE is -2.07%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, SNDX is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check EXEL's competition here
SNDX vs JAZZ Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, JAZZ has a market cap of 11.6B. Regarding current trading prices, SNDX is priced at $23.88, while JAZZ trades at $188.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas JAZZ's P/E ratio is -32.24. In terms of profitability, SNDX's ROE is -2.07%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, SNDX is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check JAZZ's competition here
SNDX vs RNAM Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, SNDX is priced at $23.88, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas RNAM's P/E ratio is -17.39. In terms of profitability, SNDX's ROE is -2.07%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, SNDX is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check RNAM's competition here
SNDX vs BMRN Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, BMRN has a market cap of 11B. Regarding current trading prices, SNDX is priced at $23.88, while BMRN trades at $57.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas BMRN's P/E ratio is 31.80. In terms of profitability, SNDX's ROE is -2.07%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, SNDX is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check BMRN's competition here
SNDX vs RXDX Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, SNDX is priced at $23.88, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas RXDX's P/E ratio is -56.47. In terms of profitability, SNDX's ROE is -2.07%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, SNDX is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check RXDX's competition here
SNDX vs ARWR Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, ARWR has a market cap of 8.8B. Regarding current trading prices, SNDX is priced at $23.88, while ARWR trades at $62.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas ARWR's P/E ratio is 39.32. In terms of profitability, SNDX's ROE is -2.07%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, SNDX is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check ARWR's competition here
SNDX vs AXSM Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, AXSM has a market cap of 8.8B. Regarding current trading prices, SNDX is priced at $23.88, while AXSM trades at $171.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas AXSM's P/E ratio is -46.68. In terms of profitability, SNDX's ROE is -2.07%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, SNDX is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check AXSM's competition here
SNDX vs IMGN Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, SNDX is priced at $23.88, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas IMGN's P/E ratio is -111.55. In terms of profitability, SNDX's ROE is -2.07%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, SNDX is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check IMGN's competition here
SNDX vs PCVX Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, SNDX is priced at $23.88, while PCVX trades at $58.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas PCVX's P/E ratio is -10.39. In terms of profitability, SNDX's ROE is -2.07%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, SNDX is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check PCVX's competition here
SNDX vs TECH Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, TECH has a market cap of 8.4B. Regarding current trading prices, SNDX is priced at $23.88, while TECH trades at $53.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas TECH's P/E ratio is 100.91. In terms of profitability, SNDX's ROE is -2.07%, compared to TECH's ROE of +0.04%. Regarding short-term risk, SNDX is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check TECH's competition here
SNDX vs BPMC Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, SNDX is priced at $23.88, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas BPMC's P/E ratio is -51.58. In terms of profitability, SNDX's ROE is -2.07%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, SNDX is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check BPMC's competition here
SNDX vs CYTK Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, CYTK has a market cap of 8.2B. Regarding current trading prices, SNDX is priced at $23.88, while CYTK trades at $66.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas CYTK's P/E ratio is -10.19. In terms of profitability, SNDX's ROE is -2.07%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, SNDX is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check CYTK's competition here
SNDX vs CERE Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, SNDX is priced at $23.88, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas CERE's P/E ratio is -16.47. In terms of profitability, SNDX's ROE is -2.07%, compared to CERE's ROE of -0.72%. Regarding short-term risk, SNDX is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check CERE's competition here
SNDX vs NUVL Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, NUVL has a market cap of 7.7B. Regarding current trading prices, SNDX is priced at $23.88, while NUVL trades at $105.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas NUVL's P/E ratio is -18.06. In terms of profitability, SNDX's ROE is -2.07%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, SNDX is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check NUVL's competition here
SNDX vs HALO Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, HALO has a market cap of 7.7B. Regarding current trading prices, SNDX is priced at $23.88, while HALO trades at $65.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas HALO's P/E ratio is 25.55. In terms of profitability, SNDX's ROE is -2.07%, compared to HALO's ROE of +0.93%. Regarding short-term risk, SNDX is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check HALO's competition here
SNDX vs KRYS Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, KRYS has a market cap of 7.6B. Regarding current trading prices, SNDX is priced at $23.88, while KRYS trades at $258.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas KRYS's P/E ratio is 37.80. In terms of profitability, SNDX's ROE is -2.07%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, SNDX is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check KRYS's competition here
SNDX vs ABVX Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, ABVX has a market cap of 7.5B. Regarding current trading prices, SNDX is priced at $23.88, while ABVX trades at $114.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas ABVX's P/E ratio is -20.60. In terms of profitability, SNDX's ROE is -2.07%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, SNDX is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check ABVX's competition here
SNDX vs MTSR Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, SNDX is priced at $23.88, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas MTSR's P/E ratio is -23.58. In terms of profitability, SNDX's ROE is -2.07%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, SNDX is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check MTSR's competition here
SNDX vs IBRX Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, IBRX has a market cap of 7.3B. Regarding current trading prices, SNDX is priced at $23.88, while IBRX trades at $7.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas IBRX's P/E ratio is -18.79. In terms of profitability, SNDX's ROE is -2.07%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, SNDX is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for SNDX.Check IBRX's competition here
SNDX vs KYMR Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, KYMR has a market cap of 6.9B. Regarding current trading prices, SNDX is priced at $23.88, while KYMR trades at $84.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas KYMR's P/E ratio is -23.02. In terms of profitability, SNDX's ROE is -2.07%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, SNDX is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check KYMR's competition here
SNDX vs MRUS Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, SNDX is priced at $23.88, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas MRUS's P/E ratio is -17.05. In terms of profitability, SNDX's ROE is -2.07%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, SNDX is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check MRUS's competition here
SNDX vs PRAX Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, PRAX has a market cap of 6.8B. Regarding current trading prices, SNDX is priced at $23.88, while PRAX trades at $319.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas PRAX's P/E ratio is -23.67. In terms of profitability, SNDX's ROE is -2.07%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, SNDX is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for SNDX.Check PRAX's competition here
SNDX vs ACLX Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, SNDX is priced at $23.88, while ACLX trades at $114.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas ACLX's P/E ratio is -28.19. In terms of profitability, SNDX's ROE is -2.07%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, SNDX is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check ACLX's competition here
SNDX vs PTGX Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, PTGX has a market cap of 6.6B. Regarding current trading prices, SNDX is priced at $23.88, while PTGX trades at $103.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas PTGX's P/E ratio is -50.57. In terms of profitability, SNDX's ROE is -2.07%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, SNDX is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check PTGX's competition here
SNDX vs BLTE Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, BLTE has a market cap of 6.6B. Regarding current trading prices, SNDX is priced at $23.88, while BLTE trades at $167.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas BLTE's P/E ratio is -72.40. In terms of profitability, SNDX's ROE is -2.07%, compared to BLTE's ROE of -0.43%. Regarding short-term risk, SNDX is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check BLTE's competition here
SNDX vs RETA Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, SNDX is priced at $23.88, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas RETA's P/E ratio is -66.29. In terms of profitability, SNDX's ROE is -2.07%, compared to RETA's ROE of +0.47%. Regarding short-term risk, SNDX is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check RETA's competition here
SNDX vs RYTM Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, RYTM has a market cap of 6B. Regarding current trading prices, SNDX is priced at $23.88, while RYTM trades at $88.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas RYTM's P/E ratio is -28.33. In terms of profitability, SNDX's ROE is -2.07%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, SNDX is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check RYTM's competition here
SNDX vs ALKS Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, ALKS has a market cap of 5.8B. Regarding current trading prices, SNDX is priced at $23.88, while ALKS trades at $35.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas ALKS's P/E ratio is 24.51. In terms of profitability, SNDX's ROE is -2.07%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, SNDX is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for SNDX.Check ALKS's competition here
SNDX vs COGT Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, COGT has a market cap of 5.7B. Regarding current trading prices, SNDX is priced at $23.88, while COGT trades at $35.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas COGT's P/E ratio is -16.31. In terms of profitability, SNDX's ROE is -2.07%, compared to COGT's ROE of -1.00%. Regarding short-term risk, SNDX is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for SNDX.Check COGT's competition here
SNDX vs PTCT Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, PTCT has a market cap of 5.7B. Regarding current trading prices, SNDX is priced at $23.88, while PTCT trades at $68.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas PTCT's P/E ratio is 8.01. In terms of profitability, SNDX's ROE is -2.07%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, SNDX is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check PTCT's competition here
SNDX vs SRRK Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, SNDX is priced at $23.88, while SRRK trades at $49.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas SRRK's P/E ratio is -15.00. In terms of profitability, SNDX's ROE is -2.07%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, SNDX is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check SRRK's competition here
SNDX vs CGON Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, CGON has a market cap of 5.6B. Regarding current trading prices, SNDX is priced at $23.88, while CGON trades at $66.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas CGON's P/E ratio is -32.11. In terms of profitability, SNDX's ROE is -2.07%, compared to CGON's ROE of -0.23%. Regarding short-term risk, SNDX is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check CGON's competition here
SNDX vs CDTX Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, SNDX is priced at $23.88, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas CDTX's P/E ratio is -19.77. In terms of profitability, SNDX's ROE is -2.07%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, SNDX is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check CDTX's competition here
SNDX vs ABCM Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, SNDX is priced at $23.88, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, SNDX's ROE is -2.07%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, SNDX is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check ABCM's competition here
SNDX vs ISEE Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, SNDX is priced at $23.88, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas ISEE's P/E ratio is -22.44. In terms of profitability, SNDX's ROE is -2.07%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, SNDX is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check ISEE's competition here
SNDX vs CELC Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, CELC has a market cap of 5.5B. Regarding current trading prices, SNDX is priced at $23.88, while CELC trades at $112.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas CELC's P/E ratio is -29.80. In terms of profitability, SNDX's ROE is -2.07%, compared to CELC's ROE of -2.03%. Regarding short-term risk, SNDX is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check CELC's competition here
SNDX vs CAI Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, CAI has a market cap of 5.4B. Regarding current trading prices, SNDX is priced at $23.88, while CAI trades at $19.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas CAI's P/E ratio is -5.94. In terms of profitability, SNDX's ROE is -2.07%, compared to CAI's ROE of +0.25%. Regarding short-term risk, SNDX is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check CAI's competition here
SNDX vs TGTX Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, TGTX has a market cap of 5.4B. Regarding current trading prices, SNDX is priced at $23.88, while TGTX trades at $33.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas TGTX's P/E ratio is 12.12. In terms of profitability, SNDX's ROE is -2.07%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, SNDX is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check TGTX's competition here
SNDX vs CNTA Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, CNTA has a market cap of 5.4B. Regarding current trading prices, SNDX is priced at $23.88, while CNTA trades at $39.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas CNTA's P/E ratio is -21.09. In terms of profitability, SNDX's ROE is -2.07%, compared to CNTA's ROE of -0.51%. Regarding short-term risk, SNDX is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check CNTA's competition here
SNDX vs FBIOX Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, FBIOX has a market cap of 5.4B. Regarding current trading prices, SNDX is priced at $23.88, while FBIOX trades at $25.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas FBIOX's P/E ratio is N/A. In terms of profitability, SNDX's ROE is -2.07%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, SNDX is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check FBIOX's competition here
SNDX vs APLS Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, APLS has a market cap of 5.2B. Regarding current trading prices, SNDX is priced at $23.88, while APLS trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas APLS's P/E ratio is 224.39. In terms of profitability, SNDX's ROE is -2.07%, compared to APLS's ROE of +0.08%. Regarding short-term risk, SNDX is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check APLS's competition here
SNDX vs ERAS Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, ERAS has a market cap of 5.2B. Regarding current trading prices, SNDX is priced at $23.88, while ERAS trades at $16.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas ERAS's P/E ratio is -37.73. In terms of profitability, SNDX's ROE is -2.07%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, SNDX is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check ERAS's competition here
SNDX vs IMVT Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, IMVT has a market cap of 5.1B. Regarding current trading prices, SNDX is priced at $23.88, while IMVT trades at $25.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas IMVT's P/E ratio is -9.40. In terms of profitability, SNDX's ROE is -2.07%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, SNDX is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check IMVT's competition here
SNDX vs TERN Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, SNDX is priced at $23.88, while TERN trades at $52.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas TERN's P/E ratio is -51.25. In terms of profitability, SNDX's ROE is -2.07%, compared to TERN's ROE of -0.20%. Regarding short-term risk, SNDX is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check TERN's competition here
SNDX vs MIRM Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, MIRM has a market cap of 4.7B. Regarding current trading prices, SNDX is priced at $23.88, while MIRM trades at $94.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas MIRM's P/E ratio is -201.32. In terms of profitability, SNDX's ROE is -2.07%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, SNDX is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check MIRM's competition here
SNDX vs APGE Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, APGE has a market cap of 4.7B. Regarding current trading prices, SNDX is priced at $23.88, while APGE trades at $84.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas APGE's P/E ratio is -19.96. In terms of profitability, SNDX's ROE is -2.07%, compared to APGE's ROE of -0.37%. Regarding short-term risk, SNDX is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check APGE's competition here
SNDX vs CRSP Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, CRSP has a market cap of 4.7B. Regarding current trading prices, SNDX is priced at $23.88, while CRSP trades at $48.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas CRSP's P/E ratio is -7.54. In terms of profitability, SNDX's ROE is -2.07%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, SNDX is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check CRSP's competition here
SNDX vs FOLD Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, SNDX is priced at $23.88, while FOLD trades at $14.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas FOLD's P/E ratio is -160.44. In terms of profitability, SNDX's ROE is -2.07%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, SNDX is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check FOLD's competition here
SNDX vs AKRO Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, SNDX is priced at $23.88, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas AKRO's P/E ratio is -14.57. In terms of profitability, SNDX's ROE is -2.07%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, SNDX is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check AKRO's competition here
SNDX vs XENE Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, XENE has a market cap of 4.5B. Regarding current trading prices, SNDX is priced at $23.88, while XENE trades at $56.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas XENE's P/E ratio is -13.00. In terms of profitability, SNDX's ROE is -2.07%, compared to XENE's ROE of -0.56%. Regarding short-term risk, SNDX is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check XENE's competition here
SNDX vs CORT Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, CORT has a market cap of 4.5B. Regarding current trading prices, SNDX is priced at $23.88, while CORT trades at $41.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas CORT's P/E ratio is 51.20. In terms of profitability, SNDX's ROE is -2.07%, compared to CORT's ROE of +0.15%. Regarding short-term risk, SNDX is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check CORT's competition here
SNDX vs ALPN Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, SNDX is priced at $23.88, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas ALPN's P/E ratio is -101.52. In terms of profitability, SNDX's ROE is -2.07%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, SNDX is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check ALPN's competition here
SNDX vs OPT Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, SNDX is priced at $23.88, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas OPT's P/E ratio is -1.52. In terms of profitability, SNDX's ROE is -2.07%, compared to OPT's ROE of +0.88%. Regarding short-term risk, SNDX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check OPT's competition here
SNDX vs MRTX Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, SNDX is priced at $23.88, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas MRTX's P/E ratio is -4.82. In terms of profitability, SNDX's ROE is -2.07%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, SNDX is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check MRTX's competition here
SNDX vs LGND Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, LGND has a market cap of 4B. Regarding current trading prices, SNDX is priced at $23.88, while LGND trades at $199.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas LGND's P/E ratio is 32.62. In terms of profitability, SNDX's ROE is -2.07%, compared to LGND's ROE of +0.14%. Regarding short-term risk, SNDX is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check LGND's competition here
SNDX vs CRNX Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, CRNX has a market cap of 3.8B. Regarding current trading prices, SNDX is priced at $23.88, while CRNX trades at $36.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas CRNX's P/E ratio is -7.39. In terms of profitability, SNDX's ROE is -2.07%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, SNDX is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check CRNX's competition here
SNDX vs VKTX Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, SNDX is priced at $23.88, while VKTX trades at $32.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas VKTX's P/E ratio is -10.33. In terms of profitability, SNDX's ROE is -2.07%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, SNDX is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check VKTX's competition here
SNDX vs ACAD Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, SNDX is priced at $23.88, while ACAD trades at $22.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas ACAD's P/E ratio is 9.70. In terms of profitability, SNDX's ROE is -2.07%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, SNDX is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check ACAD's competition here
SNDX vs NAMS Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, NAMS has a market cap of 3.8B. Regarding current trading prices, SNDX is priced at $23.88, while NAMS trades at $32.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas NAMS's P/E ratio is -19.08. In terms of profitability, SNDX's ROE is -2.07%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, SNDX is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check NAMS's competition here
SNDX vs RYZB Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, SNDX is priced at $23.88, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas RYZB's P/E ratio is -57.86. In terms of profitability, SNDX's ROE is -2.07%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, SNDX is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check RYZB's competition here
SNDX vs CBAY Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, SNDX is priced at $23.88, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas CBAY's P/E ratio is -32.81. In terms of profitability, SNDX's ROE is -2.07%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, SNDX is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check CBAY's competition here
SNDX vs KNSA Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, KNSA has a market cap of 3.6B. Regarding current trading prices, SNDX is priced at $23.88, while KNSA trades at $48.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas KNSA's P/E ratio is 64.17. In terms of profitability, SNDX's ROE is -2.07%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, SNDX is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check KNSA's competition here
SNDX vs EWTX Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, EWTX has a market cap of 3.6B. Regarding current trading prices, SNDX is priced at $23.88, while EWTX trades at $33.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas EWTX's P/E ratio is -20.33. In terms of profitability, SNDX's ROE is -2.07%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, SNDX is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check EWTX's competition here
SNDX vs SWTX Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, SNDX is priced at $23.88, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas SWTX's P/E ratio is -13.78. In terms of profitability, SNDX's ROE is -2.07%, compared to SWTX's ROE of -0.45%. Regarding short-term risk, SNDX is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check SWTX's competition here
SNDX vs LEGN Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, LEGN has a market cap of 3.5B. Regarding current trading prices, SNDX is priced at $23.88, while LEGN trades at $19.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas LEGN's P/E ratio is -11.76. In terms of profitability, SNDX's ROE is -2.07%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, SNDX is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check LEGN's competition here
SNDX vs LQDA Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, LQDA has a market cap of 3.3B. Regarding current trading prices, SNDX is priced at $23.88, while LQDA trades at $37.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas LQDA's P/E ratio is -46.84. In terms of profitability, SNDX's ROE is -2.07%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, SNDX is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check LQDA's competition here
SNDX vs DNTH Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, DNTH has a market cap of 3.2B. Regarding current trading prices, SNDX is priced at $23.88, while DNTH trades at $84.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas DNTH's P/E ratio is -20.13. In terms of profitability, SNDX's ROE is -2.07%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, SNDX is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check DNTH's competition here
SNDX vs TLX Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, TLX has a market cap of 3.1B. Regarding current trading prices, SNDX is priced at $23.88, while TLX trades at $9.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas TLX's P/E ratio is -462.00. In terms of profitability, SNDX's ROE is -2.07%, compared to TLX's ROE of -0.02%. Regarding short-term risk, SNDX is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check TLX's competition here
SNDX vs DNLI Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, DNLI has a market cap of 3.1B. Regarding current trading prices, SNDX is priced at $23.88, while DNLI trades at $19.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas DNLI's P/E ratio is -6.63. In terms of profitability, SNDX's ROE is -2.07%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, SNDX is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check DNLI's competition here
SNDX vs CPRX Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, CPRX has a market cap of 3.1B. Regarding current trading prices, SNDX is priced at $23.88, while CPRX trades at $24.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas CPRX's P/E ratio is 14.77. In terms of profitability, SNDX's ROE is -2.07%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, SNDX is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check CPRX's competition here
SNDX vs ARQT Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, ARQT has a market cap of 3B. Regarding current trading prices, SNDX is priced at $23.88, while ARQT trades at $24.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas ARQT's P/E ratio is -185.38. In terms of profitability, SNDX's ROE is -2.07%, compared to ARQT's ROE of -0.10%. Regarding short-term risk, SNDX is more volatile compared to ARQT. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check ARQT's competition here
SNDX vs TARS Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, TARS has a market cap of 3B. Regarding current trading prices, SNDX is priced at $23.88, while TARS trades at $70.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas TARS's P/E ratio is -44.16. In terms of profitability, SNDX's ROE is -2.07%, compared to TARS's ROE of -0.20%. Regarding short-term risk, SNDX is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check TARS's competition here
SNDX vs DYN Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, DYN has a market cap of 3B. Regarding current trading prices, SNDX is priced at $23.88, while DYN trades at $18.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas DYN's P/E ratio is -5.22. In terms of profitability, SNDX's ROE is -2.07%, compared to DYN's ROE of -0.61%. Regarding short-term risk, SNDX is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check DYN's competition here
SNDX vs SYRE Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, SYRE has a market cap of 3B. Regarding current trading prices, SNDX is priced at $23.88, while SYRE trades at $48.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas SYRE's P/E ratio is -24.70. In terms of profitability, SNDX's ROE is -2.07%, compared to SYRE's ROE of -0.29%. Regarding short-term risk, SNDX is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check SYRE's competition here
SNDX vs TVTX Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, TVTX has a market cap of 2.9B. Regarding current trading prices, SNDX is priced at $23.88, while TVTX trades at $31.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas TVTX's P/E ratio is -59.29. In terms of profitability, SNDX's ROE is -2.07%, compared to TVTX's ROE of -0.79%. Regarding short-term risk, SNDX is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for SNDX.Check TVTX's competition here
SNDX vs VERA Comparison April 2026
SNDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNDX stands at 2.1B. In comparison, VERA has a market cap of 2.9B. Regarding current trading prices, SNDX is priced at $23.88, while VERA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNDX currently has a P/E ratio of -7.26, whereas VERA's P/E ratio is -8.69. In terms of profitability, SNDX's ROE is -2.07%, compared to VERA's ROE of -0.60%. Regarding short-term risk, SNDX is more volatile compared to VERA. This indicates potentially higher risk in terms of short-term price fluctuations for SNDX.Check VERA's competition here